**Core tip:** Gastrointestinal cancers are among the leading causes of cancer morbidity and mortality worldwide. So far, various targeted agents associated with predictive biomarkers are available or are under development for the selection of treatment in patients with gastrointestinal cancer. Advances in high-throughput technologies such as next generation sequencing and the use of noninvasive materials for tumor characterization, such as liquid biopsies, will facilitate tumor molecular profiling and lead to the establishment of further targeted treatment therapies.

INTRODUCTION
============

The comprehension of the importance of tumor biology has led to the development of new drugs that target specific molecules involved in carcinogenesis. The efficacy of such targeted therapies often depends on the presence or absence of gene alterations that encode for the protein-target or for proteins involved in the molecular pathway targeted by the specific medication. This targeted therapeutical approach is based on the tumor's molecular analysis in order to select patients with increased probability to respond to the treatment given. Advances in Molecular Biology techniques have permitted comprehensive tumor genomic profiling using new breakthrough technologies such as next generation sequencing (NGS)\[[@B1]-[@B3]\].

Nowadays, biomarkers are used in the management of patients with cancer and can be divided into predictive and prognostic. Prognostic biomarkers are defined as those that provide information on the possible outcome of cancer in a particular patient regardless of treatment. Predictive biomarkers provide information on the potential benefit of the administrated treatment (whether this relates to the tumor's volume shrinkage or survival). Predictive biomarkers can be used to identify subpopulations of patients that are likely to respond to a particular treatment\[[@B1]\]. They can be subdivided in positive and negative predictive biomarkers. The first are used for positive selection of patients who are likely to benefit from targeted therapy, whereas the latter for resistance prediction\[[@B1]\].

The number of genes involved in targeted therapy (predictive biomarkers), is increasing continuously. The simultaneous analysis of these biomarkers is feasible using molecular biology technologies that allow accurate, fast and cost effective genomic analysis with limited requirements concerning the quantity of the biological material used\[[@B1],[@B4]\]. ΝGS has all the features required to carry out such analysis and provides simultaneous information on a large number of actionable alterations in tumor tissues and thus a more precise molecular characterization of the tumor. The massive amount of genetic information produced is the main advantage of this technology. However, it also constitutes its main challenge, requiring usage of appropriate software and bioinformatics tools, along with web-based tools for data analysis, management and interpretation\[[@B5]\].

The human gastrointestinal (GI) tract is an organ system which includes all structures between mouth and anus and is divided into upper (buccal cavity, pharynx, esophagus, stomach and duodenum) and lower (small and large intestine) GI tracts. GI cancers are complex diseases and refer to malignant conditions that affect the digestive system. The current review will focus on the advances in the field of molecular biomarkers and the application of high throughput technologies, in the most common tumors of the gastrointestinal tract.

Esophageal cancer
-----------------

Esophageal cancer is one of the most aggressive malignancies with a rapidly increasing incidence rate in the recent decades. There are two predominant histological types: Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) of the distal esophagus and the gastroesophageal junction. Smoking and heavy alcohol consumption are associated with increased risk of ESCC, while gastroesophageal reflux disease and Barrett esophagus may of increase the risk of EAC\[[@B6]\].

*TP53* mutations are identified in about 50% of esophageal cancers and are associated with poorer survival\[[@B7]\]. Apart from mutations in *TP53* ESCC and EAC seem to differ significantly in the genetic alterations pattern. Agrawal et al\[[@B8]\] using NGS reported a substantial disparity in the spectrum of mutations, with more insertions/deletions in ESCCs, A:T\>C:G transversions in EACs, and C:G\>G:C transversions in ESCCs. Inactivating mutations of *NOTCH1* are identified in about 20% of ESCCs but not in EACs. Somatic aberrations in EACs are mainly identified in the Wnt, cell cycle and Notch pathways\[[@B9],[@B10]\]. A number of genes that can be used as predictive markers for targeted therapy have been explored for somatic mutations in esophageal adenocarcinoma, including genes of the RAF/MEK/ERK (MAPK) kinase pathway such as *EGFR, BRAF, KRAS, PIK3CA*\[[@B11]\]. However the reported frequency of somatic mutations identified appears to be low and this is obvious when accessing data from the Catalogue of Somatic Mutations in Cancer database (COSMIC, cancer.sanger.ac.uk) (Figure [1](#F1){ref-type="fig"}), which is currently the most comprehensive global resource accessing the world literature on somatic mutations in human cancer\[[@B12]\]. In a recent study, NGS-based comprehensive genomic profiling was used to analyze ESCC and EAC tumors\[[@B13]\]. The analysis showed that the esophageal histotypes differ significantly in genomic alterations profile, with *KRAS* and *ERBB2* far more frequently altered in EAC compared to ESCC. In contrast, genes of the mechanistic target of rapamycin (MTOR) pathway (*PIK3CA* and *PTEN*) and *NOTCH1* are more frequently altered in ESCC compared to EAC. They also have different amplification patterns (Figure [2](#F2){ref-type="fig"}).
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ESCC and EAC also differ in the gene amplification and/or protein (over)expression of the receptor tyrosin kinases (RTKs) EGFR and HER2 making them possible prognostic markers and as therapeutic targets\[[@B7],[@B14]\]. EGFR is frequently overexpressed in ESCCs, while HER2 overexpression occurs mainly in EACs. Thus the trastuzumab-platinum regimen is currently used for the 15% of the EACs patients that test positive for HER2 (ERBB2) amplification or overexpression\[[@B13],[@B14]\].

Numerous preclinical studies addressed EGFR and HER2 inhibition in esophageal cancer cell lines and there are various phase II/III clinical trials testing EGFR, HER2, and VEGF targeting therapies for esophageal cancer\[[@B7],[@B15]\]. However, the results obtained to date do not allow the use of these agents in clinical practice. Upon trial completion several clinical studies have concluded, that in order to select patients who will respond to RTK-targeted therapy, there is a need for molecular patient stratification before treatment.

In a disease with historically poor outcomes and limited options, comprehensive genomic profiling of relapsed and refractory cancers, including distinct evaluation for EAC and ESCC has led to promising information suggesting targeted therapies for future consideration.

Gastric cancer
--------------

Gastric cancer (GC) develops from the inner lining of the stomach and is a very aggressive malignancy, with poor prognosis and very high cancer related mortality. The high mortality rate is largely due to the late stages of cancer diagnosis and to the lack of effective medical treatment for advanced stages of this disease\[[@B16],[@B17]\]. The majority of these cancers are adenocarcinomas and can be further classified as diffuse (poorly differentiated) or intestinal (well-differentiated) types that have distinct molecular profiles\[[@B16],[@B17]\].

Concerning the causes of GC, it can be viewed as a multifactorial disease since many inherited and environmental factors play a role in its development. Infectious agents such as Helicobacter pylori and EBV, dietary habits and the genetic background are considered as causative agents\[[@B17]\].

Given the variety of causes of the disease, it is not surprising that these tumors present a high level of biological heterogeneity, with distinct molecular profile for each patient. Genetic and epigenetic alterations play important role in GCs therefore, targeted therapy based on the biology of the individual patient could improve treatment outcome\[[@B17]-[@B19]\].

ERBB2 amplifications occur frequently in gastric tumors (2%-27%)\[[@B12],[@B20]\]. Trastuzumab, a monoclonal antibody against HER2/neu receptor, was the first targeted agent to be used in the treatment of ERBB2-positive advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma\[[@B20]\]. Several molecular targeted agents associated with a survival benefit in other cancer types are now under clinical investigation for the treatment of gastric cancer, including inhibitors of EGFR, MET, FGFR, VEGF, and PI3K\[[@B18],[@B20]\]. Additionally, *CDH1* gene mutations at the somatic level are considered of prognostic significance\[[@B19]\].

Several studies have investigated gastric cancer's molecular profile using whole genome as well as targeted NGS approaches\[[@B19],[@B21]-[@B23]\]. The presence of somatic mutations and copy number variations (CNV) in many cancer driver genes has been revealed. Among the cancer genes frequently mutated in gastric cancer *P53*, *ARD1A*, *CDH1*, *PIK3CA*, *APC, CTNNB1, ERBB3, ATM, KRAS* are the most important prognostic and/or predictive markers (Figure [3](#F3){ref-type="fig"})\[[@B12]\]. Consequently, molecular profile-directed therapy seems to be a promising strategy for the improvement of standard chemotherapy effectiveness.
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CNVs have been observed for HER2, FGFR2, and MET that represent viable treatment targets for which therapeutics are already approved or are currently under investigation\[[@B24]\] (Figure [4](#F4){ref-type="fig"}).
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The high heterogeneity of these tumors triggered scientists to attempt their molecular characterization. In a study conducted by The Cancer Genome Atlas, molecular classification four major genomic subtypes of gastric cancer were defined: EBV-infected tumors; MSI tumors; genomically stable tumors; and chromosomally unstable tumors\[[@B21]\].

In a recent study, Li et al\[[@B19]\], using whole genome NGS data were able to classify gastric cancers into regular (86.8%) and hyper-mutated (13.2%) subtypes based on mutation burden. Additionally, in the "regular" mutated cohort a further classification, using 40 significantly mutated genes, could be obtained, separating the patients to S1 and S2 subtypes with distinct prognostic outcomes.

Gastrointestinal stromal tumors
-------------------------------

Gastrointestinal stromal tumors (GISTs) are rare tumors of the gastrointestinal tract. They are mesenchymal in origin and are characterized by overexpression of the KIT protein\[[@B25]\]. Morphological diagnosis based on microscopic examination is the standard for GIST diagnosis. They occur anywhere within the GI tract, but they are most common in the stomach (60%) or small intestine (30%)\[[@B26]\]. Their diagnosis is based on the expression of the transmembrane tyrosine kinase (TK) receptor, KIT, since 95% of GISTs express CD 117 antibody. In 80% of the cases, somatic mutations in the *cKIT* gene are observed, resulting in constitute receptor activation. Additionally, in 5%-10% of the cases without *cKIT* mutations, the TK receptor *PDGFRA* is mutated\[[@B27]\]. The mutation spectrum of these tumors is very limited as we observe in COSMIC database (Figure [5](#F5){ref-type="fig"})\[[@B12]\]. Tyrosine kinase inhibitors (TKIs) like imatinib, sunitinib, and more recently regorafenib, have proven effectiveness in suppressing the growth of metastatic GISTs, allowing patients to live far longer than during the previous era of ineffective chemotherapy\[[@B28]-[@B30]\]. The response to targeted therapy with TKIs is mainly dependent on the presence and type of mutation. Patients with mutations in exon 11 of the *cKIT* are highly responsive to imatinib, while the presence of a mutation in exon 9 of this gene implies intermediate response rates and necessitates a double dose of drug administration. Furthermore, resistance mutations to imatinib are also observed in the *cΚΙΤ/PDGFRA* genes. These mutations can be present in the primary tumor or arise as a result of the drug administration (secondary mutations)\[[@B29]\].
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Colorectal cancer
-----------------

The cancer of colon and rectum (colorectal, CRC) is the third most common cancer worldwide with 95% of these tumors being classified as adenocarcinomas. It's a leading cause of cancer related deaths; however, colorectal cancer mortality is declining in the last decades, mainly due to early diagnosis and the presence of new therapy strategies\[[@B31],[@B32]\]. This malignancy is one of the first paradigms of the benefits that can be derived from the application of personalized treatment in cancer therapy\[[@B33]-[@B35]\].

Genetic alterations in colorectal cancer include mainly single-base substitutions (SBS). Nevertheless, small insertions and deletions (indels), amplifications, homozygous deletions and translocations can also be observed\[[@B36]\].

Five hundred and seventy-two cancer relevant genes are included in the Catalogue of Somatic Mutations in Cancer (COSMIC, cancer.sanger.ac.uk)\[[@B12]\]. Somatic mutations in CRC cancer are observed in the majority of these genes. The pattern of genomic alterations was identified through Massively Parallel Sequencing studies, revealing the inter- and intra-tumor genetic heterogeneity of these tumors\[[@B37]-[@B39]\]. Apart from single base substitutions, gene amplifications are also observed (Figure [6](#F6){ref-type="fig"}). Mutations in many important biologic pathways occur. In Table [1](#T1){ref-type="table"} the frequency of mutations in important molecular signaling pathways and the related therapies are represented. The gene mutation frequency is calculated using data from samples analysed by whole genome screening in the COSMIC database. The information concerning the therapies targeting each pathway was retrieved from MyCancer Genome knowledge database ([www.mycancergenome.org/](www.mycancergenome.org/)), that provides reliable information concerning important cancer related genes and their correlation with treatment options (Table [1](#T1){ref-type="table"})\[[@B40]\].

###### 

Overall gene mutation frequency in each molecular signaling pathway

  **Biologic pathway**                               **Frequency of mutation in genes involved in each pathway**   **Therapies that target the pathway**
  -------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------------------------------
  Beta-catenin/WNT signaling                         75%                                                           FZD, GSK inhibitors
  Cell cycle control                                 68%                                                           CDK, CDK1, CDK2, CDK4/6 inhibitors
  Receptor tyrosine kinase/growth factor signaling   67%                                                           Therapeutic antibodies/tyrosine kinase inhibitors
  MAP kinase signaling                               61%                                                           BRAF, ERK, MEK AND SRC inhibitors
  PI3K/AKT1/MTOR                                     52%                                                           Allosteric mTORC1 inhibitors/mTORC1/2 catalytic inhibitors
  DNA damage/repair                                  48%                                                           PARP INHIBITORS
  TGFbeta signaling                                  37%                                                           TGFBR1 inhibitors
  Chromatin remodeling/DNA methylation               32%                                                           DNMT inhibitors, Histone deactylase
  Immune checkpoints                                 26%                                                           Anti-CTLA4 antibodies, anti-PD-1 antibodies, Anti-PD-L1 antibodies, Immunotherapies
  JAK/STAT signaling                                 23%                                                           JAK inhibitors
  Hedgehog signaling                                 12%                                                           SMO inhibitors

The information concerning therapies that target each molecular pathway was retrieved for MyCancer Genome Site (Available from: URL: http//[www.mycancergenome.org/](www.mycancergenome.org/)).
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The *RAS* proto-oncogenes (*HRAS, KRAS* and *NRAS*) encode a family of highly homologous proteins. They participate in a signal transduction cascade, namely the RAS/RAF/MEK/ERK pathway, which regulates the growth and survival properties of the cells. They are controlled by extracellular signals transmitted by the transmembrane receptor tyrosine kinase (TK), EGFR\[[@B34]\]. This TK and the RAS/RAF/MEK/ERK pathways it controls, play an important role in colorectal carcinogenesis, making it a good target for biological therapy of this disease.

Two monoclonal antibodies were designed as effective inhibitors of EGFR. Cetuximab (Erbitux, Merck KgaA, Darmstadt, Germany) is a chimeric mouse/human antibody, and Panitumumab (Vectibix, Amgen Thousand Oaks, CA, United States), is a fully human antibody\[[@B33]-[@B35]\]. They both target the extracellular domain of the EGFR protein and compete with ligands, blocking ligand induced intracellular signal transmission. However, anti-EGFR treatment is not effective in patients harboring activating mutations in genes that participate in the intracellular transduction RAS/RAF/MEK/ERK pathway. This is due to the constitutive, independent of ligand, activation of the mutated proteins\[[@B33]\].

In total, activating mutations in the *RAS* genes, mainly in codons 12, 13 or 61, occur in approximately 20% of all human cancers. Mutations in *KRAS* account for about 85% of all *RAS* mutations in human tumors, *NRAS* for about 15%, and *HRAS* for less than 1%\[[@B41],[@B42]\]. Which particular *RAS* gene is mutated seems to be tumor specific. Colonic, pancreatic and lung cancers have high frequencies of *KRAS* mutations\[[@B41],[@B42]\].

Acquired mutations in *KRAS* and *NRAS* are commonly used to identify colorectal cancer patients who are unlikely to benefit from anti-EGFR therapy. Approximately 40% of colorectal cancer tumors harbor mutations in the *KRAS* gene, with the majority of the mutations occurring in codons 12, 13 and 61. In 5% of the colorectal cancer cases a mutation occurs in the *NRAS* gene\[[@B35],[@B41]\].

Another important gene of the RAS/RAF/MEK/ERK pathway is *BRAF*. Mutations in the *BRAF* gene (exons 11 and 15) have been detected in about 12% of colorectal cancers and are mutually exclusive with *RAS* mutations\[[@B12],[@B43],[@B44]\]. The *BRAF* activating aberrations, result in constitutive BRAF kinase activity, ERK signaling, proliferation and transformation\[[@B44]\]. The majority of *BRAF* mutations are observed in exon 15 (codon 600) and a minority of mutations are observed in exon 11\[[@B44],[@B45]\].

Several studies have reported that patients with metastatic CRC (mCRC) that harbor *BRAF* mutations do not respond to the anti-EGFR antibody agents cetuximab or panitumumab\[[@B43],[@B46],[@B47]\]. However it is unclear if the presence of *BRAF* mutations in CRC cancer can be used as a predictive marker or if it has only a prognostic value, independent of treatment, since different studies arrive at controversial conclusions concerning its clinical significance\[[@B45],[@B48]\].

The *PIK3CA* gene encodes the catalytic subunit of phosphatidylinositol 3-kinase while belongs to a family of lipid kinases. These kinases regulate a diverse range of cellular processes including cell proliferation, adhesion, survival, and migration\[[@B49]\]. Mutations in *PIK3CA* stimulate downstream AKT-mTOR signaling pathways, thereby promoting growth-factor independent growth, cell invasion and metastasis. *PIK3CA* mutations have been reported in multiple malignancies, including approximately 25% of gastric, 4% of lung, 25% of breast, and 20% of colorectal cancers\[[@B50]\]. The majority (80%) of *PIK3CA* mutations cluster in 2 "hotspot" regions, the helical domain (exon 9) and the kinase domain (exon 20). Concomitant *PIK3CA* mutations in exons 9 and 20 seem to be linked to significantly worse cancer-specific survival\[[@B51]\]. *PIK3CA* mutations may also be associated with clinical resistance to EGFR-targeted monoclonal antibodies, but there have been conflicting results\[[@B52]-[@B55]\]. A meta-analysis comprising 864 patients, from 11 studies, with colorectal cancer treated with cetuximab or panitumumab-based therapy showed that *PIK3CA* mutations, particularly in exon 20, are significantly associated with worse response and shorter progression-free and overall survival\[[@B51]\]. Somatic *PIK3CA* mutations have also been associated with superior colorectal cancer-specific survival in patients who regularly intake aspirin after diagnosis\[[@B56]\]. *PIK3CA* activating mutations may also predict sensitivity to inhibitors of the PI3K-AKT-mTOR pathway\[[@B57]\]. Inhibitors of mTOR, PI3K, and AKT, alone or in combination with other therapies are in clinical trials in solid tumors\[[@B58],[@B59]\].

A number of rare gene mutations occurring in the PI3K/AKT/mTOR pathway are potentially actionable in colorectal cancer. PTEN is a key negative regulator of the PI3K pathway. *PTEN* gene mutations occur in about 5% of colorectal cancers\[[@B12],[@B60],[@B61]\]. *PTEN* inactivating mutations and *PTEN* loss have as a consequence the upregulation of the PI3K/ AKT pathway\[[@B54],[@B61]\].

Currently, the prognostic and predictive significance of *PTEN* mutations or *PTEN* loss of expression is under investigation. In retrospective studies, *PTEN* loss was associated with decreased sensitivity of colorectal cancer tumors to anti-EGFR antibodies\[[@B60]-[@B62]\]. Preclinical data and *in vitro* studies suggest that it may be associated with sensitivity to PI3K and mTOR inhibitors. Based on these data, several PI3K and mTOR inhibitors are currently in clinical trials for the treatment of patients with PTEN-deficient cancers\[[@B61],[@B63]\].

AKT (Protein kinase B, PKB) is a serine/threonine kinase that is encoded by three genes AKT1, 2 and 3. Somatic mutations in the *AKT1* gene occur in colorectal cancer in about 1% of the cases according to the COSMIC database\[[@B12]\]. The only mutation observed is the activating mutation *E17K*, which is also observed in other types of cancer\[[@B64]\]. AKT1 is a critical component of the PI3K/AKT/mTOR pathway, thus it has become an attractive target for therapeutic intervention\[[@B49],[@B65]\]. *AKT1 E17K* mutations have also been associated with primary resistance to cetuximab\[[@B66]\].

In colorectal cancer, DNA mismatch repair (MMR) system deficiency occurs frequently and leading to microsatellite instability (MSI). These are small changes in the DNA sequence that occur during DNA replication and are usually additions or deletions of one or two nucleotide bases\[[@B67],[@B68]\]. This phenomenon is most common in areas of the genome that contain repetitive DNA sequences with a repeat unit, from one to four bases, and are known as Microsatellite regions\[[@B67],[@B69]\]. The presence of microsatellite instability (MSI High) is a good prognostic marker\[[@B67],[@B70]\]. It is found in 90% of cases of tumors arising patients with hereditary Lynch syndrome and in 10%-15% of the sporadic cancers\[[@B71]\]. Sporadic MSI-H tumors can be distinguished from the hereditary ones through somatic mutation analysis of the *BRAF* gene or loss of *MLH1* expression\[[@B72],[@B73]\]. Somatic mutations in the *BRAF* gene occurs only in sporadic MSI-H tumors but not in Lynch-associated CRC cancers. Similarly, *hMLH1* promoter methylation rarely occurs in Lynch syndrome-associated cancers, while is common in sporadic MSI-high cancers\[[@B73]\].

Recent studies have indicated that MSI high tumors, both sporadic and hereditary, are less aggressive and are related with low probability of lymph node and distant recurrences\[[@B70]\]. In addition they respond differently to chemotherapy, since they are less sensitive to Topoisomerase inhibitors and to the treatment with 5-fluorouracil\[[@B74]-[@B76]\]. Additionally, it has been proposed that MMR-deficient tumors are more responsive to PD-1 blockade than the mismatch repair-proficient tumors\[[@B77]\].

Gene expression profiling (GEP) is an emerging tool which aims to identify differentially expressed subsets of genes (gene signatures) in groups of patients with distinct clinical outcomes. Several commercial GEP tests are currently available for stage II/IIIa colorectal cancer patients. Oncotype DX^®^ Colon Cancer Assay (Genomic Health, Inc., Redwood City, CA) and ColoPrint (Agendia, BV, Amsterdam, Holland) are the most promising gene signature tests\[[@B78]\]. Both tests provide a risk of recurrence, but OncotypeDx has the advantage of being applicable to Formalin Fixed Paraffin Embedded (FFPE) tissue for analysis, while ColoPrint requires fresh tissue which is not easily available. Oncotype DX^®^ Colon Cancer Assay is a quantitative reverse transcription polymerase chain reaction (RT-qPCR) assay on RNA extracted from FFPE tumor tissue, used to assess risk of recurrence in stage II colon cancer patients at three years after surgery\[[@B79]-[@B81]\]. The test uses gene expression profiling of 12 genes that include seven prognostic genes and five reference genes, in order to provide a Recurrence Score (RS). The RS allows patients and physicians to determine the risk of developing a distant metastasis. In a retrospectively performed study by Yothers et al\[[@B82]\], RS was the strongest predictor of disease recurrence independent of other factors, such as T-stage, mismatch repair status, number of nodes examined, tumor grade, and lymphovascular invasion. The greatest utility of this test seems to be in the prediction of recurrence risk in T3, mismatch repair-proficient (MMR-P) stage II colon cancer patients\[[@B82]\]. However, it has also been validated in stage III patients with very promising results\[[@B83]\]. The continuous RS predicted recurrence as well as disease free survival (DFS) and overall survival (OS) in all three patient subgroups (stage II, IIIA/B, and IIIC). The use of this assay could lead to overall reduction in adjuvant chemotherapy use in this subgroup of stage II/III colon cancer patients\[[@B83]\].

LIQUID BIOPSY
=============

Until recently, the best material for somatic mutation analysis was considered formalin fixed paraffin embedded (FFPE) tumor tissue. FFPE tissue is a widely available material, easy to use and maintain. In addition, the cancer tissue can be selected and mutation analysis can be performed without contamination by normal tissues\[[@B42]\]. This increases the sensitivity of mutation detection assays which is very important because, due to tumor heterogeneity, somatic mutations can sometimes be present at a very low percentage. However, FFPE tissue material also has several disadvantages\[[@B84],[@B85]\]. First of all in some cases it is not available. This is the case of non-operable tumors. Furthermore, the examination of a limited tumor area present in a paraffin block doesn't take into account tumor molecular heterogeneity and does not necessarily reflect the molecular profile of other tumors or metastasis that are eventually present in the patient's body\[[@B85]\]. Additionally, the genetic material obtained, due to the paraffinization process, is sometimes of very bad quality and not suitable for molecular analysis\[[@B86]\]. Most importantly, tumor molecular profile is altered mainly following therapy and those alterations cannot be detected by analyzing the primary tumor material\[[@B87]\].

Nowadays, the presence of cell-free tumor derived nucleic acids (ctDNA/ctRNA) in cancer patients body fluids (plasma, serum, Broncho-alveolar, urine, stool, *etc*.) is well documented\[[@B84]\]. The term Liquid Biopsy has emerged indicating the use of these noninvasive materials for tumor characterization. The mutation status detected in a liquid biopsy reflects the status present in the patient's tumor. Furthermore Liquid Biopsy analyses take into account intra-tumor or inter metastatic heterogeneity and could eventually detect more tumor alterations compared with the analysis of a specific area in a FFPE tissue\[[@B83],[@B84]\]. A variety of sensitive methods can be used for the detection of ctDNA in plasma samples, including digital PCR, Real time PCR, Arms PCR and NGS\[[@B84]\].

The utility of liquid biopsy analysis has been proven in many studies that used ctDNA for the detection of tumor specific alterations in plasma with prognostic and/or predictive significance\[[@B87]-[@B98]\]. A liquid biopsy analysis can be performed before treatment as well as for patients monitoring during therapy. It is also very helpful in the detection of secondary mutations that arise due to targeted therapy. The detection of secondary mutations in plasma can modify the treatment strategy for those patients (Table [2](#T2){ref-type="table"}).

###### 

Gene mutations identified in ctDNA of patients with tumors of the gastrointestinal tract and their correlation with possible clinical implications

  **Gene**      **Mutation type**              **Tumor type**                 **Possible clinical implications**                                    **Ref**.
  ------------- ------------------------------ ------------------------------ --------------------------------------------------------------------- ------------
  *KRAS/NRAS*   Point mutation/amplification   Colorectal/pancreatic cancer   Resistance to anti-EGFR therapy/sensitivity to MEK inhibitors         \[88-90\]
  *BRAF*        Point mutation                 Colorectal cancer              Resistance to anti-EGFR therapy/sensitivity to MEK inhibitors         \[88,91\]
  *MET*         Amplification/alteration       Colorectal/esophageal cancer   Resistance to anti-EGFR therapy/sensitivity to MEK inhibitors         \[92-94\]
  *HER2*        Amplification                  Colorectal/gastric cancer      Resistance to anti-EGFR therapy/sensitivity to Anti HER2 inhibitors   \[95,96\]
  *EGFR*        Point mutation                 Colorectal/pancreatic cancer   Panitumumab                                                           \[97,98\]
  *PIK3CA*      Point mutation                 Colorectal/pancreatic cancer   mTOR inhibitor                                                        \[89\]
  *Ckit*        Point mutations                GISTS                          Imatinib or dose escalation or alternative TKIs                       \[99,100\]
  *PDGFRA*      Point mutations                GISTS                          Imatinib or dose escalation or alternative TKIs                       \[99,100\]

TKI: Tyrosine kinase inhibitors; GIST: Gastrointestinal stromal tumors; EGFR: Epidermal growth factor receptor; mTOR: Mechanistic target of rapamycin.

NGS METHODOLOGIES
=================

NGS is a general term referring to all post-Sanger sequencing technologies that are able to massively sequence millions of DNA segments\[[@B99],[@B100]\]. The goal of these technologies is to increase sequencing capacity and speed at a lower cost. Furthermore, the sensitivity obtained is superior to that of the conventional sequencing technology, making possible the detection of mutations that are present at very low percentages in a background of normal DNA, which is very important for somatic mutation detection. Currently the most widely used platforms are those offered by Illumina, Inc. (United Sates); Thermo Fisher Scientific, Inc. (United Sates) and Roche Holding AG (Switzerland)\[[@B101]-[@B103]\]. The first NGS platform was created by Roche and used emulsion PCR (emPCR) to clonally amplify the fragments that are then sequenced *via* sequencing-by-synthesis (SBS) technology\[[@B101]\]. The Illumina platform is currently widely used in the NGS market and involves bridge amplification, of a solid surface-bound DNA, to clonally amplify the fragments that are then sequenced using SBS chemistry\[[@B102]\]. Unlike the previous two technologies, the Life technology platform uses Ion semiconductor sequencing, instead of fluorescence based sequencing, detecting the protons released as nucleotides are incorporated during synthesis\[[@B103],[@B104]\].

The past years have seen an accelerating outbreak of publications in which NGS is applied for a variety of goals such as full-genome resequencing or more targeted mutation detection. Worldwide collaborative efforts, such as COSMIC database, International Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) project, enabled to catalogue NGS data of thousands of cancer genomes across many disease types\[[@B105],[@B106]\]. Targeted NGS, involving gene panels, is a quicker and cost effective alternative to whole genome sequencing or exome sequencing. Targeted NGS panels for somatic mutation detection include actionable cancer genes and allow the determination of the patient's tumor molecular profile. The goal of their use is to increase the percentage of patients with detected actionable alterations and with copy number data, allowing them to be included in clinical trials\[[@B107]-[@B109]\].

Such panels are currently available or can be custom made. They exhibit high rates of sensitivity, specificity and repeatability; therefore they are optimal for diagnostic use. Benchtop NGS sequencers are now offered by both Illumina (MiSeq) and Thermo Fisher (PGM™ and Ion Proton™). The availability of the equipment required and the cost effectiveness of the analysis allows its implementation in local specialized laboratories\[[@B108],[@B109]\]. However, the reliability of these tests should be reassured. Thus, NGS performing laboratories should have specialized personnel and equipment which will provide adequate data analysis management and interpretation with the aid of appropriate software and bioinformatics tools. Importantly, these tests should be operated under the guidelines of a quality assurance system\[[@B110],[@B111]\].

Concerning the selection of the appropriate sequencing platform, it should be based on the individual laboratory's needs. All NGS platforms have advantages and disadvantages and the choice of the platform used should be based on the application for which it is required. For example, the MiSeq platform (Illumina) has lower error rates especially in the homo-polymer regions compared to both Ion Proton and PGM (Life Technology). However it requires higher DNA concentration and quality, which is not always available when the starting material is FFPE tissue. On the other hand, the NGS platforms offered by Thermo Fisher provide a fast and cost-effective sequencing solution with good analytical performance. Additionally, they more compatible with low DNA concentrations and partially degraded poor quality DNA from FFPE samples\[[@B107]-[@B109],[@B112]\]. Consequently, they provide an attractive option of clinical utility for the detection of cancer hotspot mutation analysis.

CONCLUSION
==========

This review summarizes the use of biomarkers in the most common cancers of the GI tract. They are used for positive selection of patients who are likely to benefit from targeted therapy or for resistance prediction. Biomarker based targeted treatment is established in a subset of patients with gastrointestinal cancer. Meta-analysis studies have shown that biomarker based treatment is a promising approach and is associated with improved treatment outcome\[[@B113]-[@B115]\]. However, ongoing clinical trials, identification of novel biomarkers as well as further advances in high-throughput technologies will hopefully result in further development of therapeutic targets, treatment strategies and improved survival for these patients in the near future.
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